Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › vismodegib

vismodegib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of vismodegib

25 trials tracked of vismodegib: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 39 citations.

25Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 2 20 Phase 1 4
  1. Phase 4 VISmodegib for ORbital and Periocular Basal Cell Carcinoma Completed · 39 cited
  2. Phase 2 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed
  3. Phase 2 Vismodegib for Treatment of Basal Cell Carcinoma Completed
  4. Phase 2 Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer Completed
  5. Phase 2 A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma Completed
  6. Phase 2 Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer Completed
Show 19 more trials
  1. Phase 2 A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Completed
  2. Phase 2 A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas Completed
  3. Phase 2 Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas Completed
  4. Phase 2 A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors Completed
  5. Phase 2 A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Completed
  6. Phase 2 Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer Completed
  7. Phase 2 Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma Completed
  8. Phase 2 Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma Completed
  9. Phase 2 A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study Completed
  10. Phase 2 My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Completed
  11. Phase 2 STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Completed
  12. Phase 2 GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Completed
  13. Phase 2 Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Completed
  14. Phase 2 Evaluation of Food Effect on Pharmacokinetics of Vismodegib Completed
  15. Phase 2 Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed
  16. Phase 1 Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) Completed
  17. Phase 1 A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy Completed
  18. Phase 1 A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function Completed
  19. Phase 1 A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis of vismodegib for periocular and orbital basal cell carcinoma
Rheumatology Meta-analysis
Systematic review and meta-analysis of vismodegib for periocular and orbital basal cell carcinoma Vismodegib shows response rates for periocular and orbital basal cell carcinoma
This systematic review and meta-analysis of 764 patients with periocular or orbital basal cell carcinoma found that vismodegib achieved comp…
A review of 764 patients found vismodegib helped shrink tumors, but side effects were common and led many to stop treatment.
Frontiers May 11, 2026